Page 18 - Flipbook

ARCHES: Enzalutamide in All-Comers 18

100

90
80
70

(%) 60
50
rPFS 40 ENZA + ADT PBO + ADT

(n = 574) (n = 576)
30 Median, month (95% CI) NR (NR, NR) 19.0 (16.59, 22.24)
20 HR (95% CI) 0.39 (0.30, 0.50)
p value <0.001
10 12-month event-free
rate estimate 0.84 0.63
0
0 3 6 9 12 15 18 21 24 27 30 33
Months
Patients at Risk
ENZA + ADT 574 493 256 62 4 0
PBO + ADT 576 445 191 39 0 0

• Median follow-up time is 14.4 months; median duration of therapy was 12.8 (range 0.2–26.6)
months for enzalutamide + ADT and 11.6 (range 0.2–24.6) months for placebo + ADT.

Enzalutamide with ADT significantly reduced the risk of metastatic progression or death
over time versus placebo plus ADT in men with mCSPC

Armstrong, Andrew J., et al. "ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive
prostate cancer." Journal of Clinical Oncology 37.32 (2019): 2974-2986.